Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribocicl...

Full description

Bibliographic Details
Main Authors: Marina Elena Cazzaniga, Antonio Ciaccio, Romano Danesi, Francois P. Duhoux, Corrado Girmenia, Kalhil Zaman, Henrik Lindman, Fabrizio Luppi, Dimitrios Mavroudis, Ida Paris, Ayodele Olubukola, Ahmed Samreen, Christian Schem, Christian Singer, Anton Snegovoy
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
CDK 4/6 inhibitors
abemaciclib
ribociclib
palbociclib
diarrhea
liver toxicity and injury
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1247270/full

Similar Items